STAAR Surgical Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by STAAR Surgical Co. on June 25, 2025. The filing primarily addresses corporate governance changes, specifically the appointment of a new Chief Financial Officer and the establishment of a new board committee.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figures disclosed relate to executive compensation:
- Base Salary: $495,000 annually for the new CFO.
- Target Bonus: 55% of base salary.
- Equity Award: Grant date fair value of $1.4 million, split between restricted stock units and performance stock units.
Material Changes
The material change reported is the appointment of Deborah Andrews as Chief Financial Officer, effective June 25, 2025. Ms. Andrews previously served as Interim CFO since March 2025 and held the CFO role from 2017 to 2020. Additionally, the Board established a new Capital Stewardship Committee to guide financial strategies and capital allocation, chaired by Board member Lilian Y. Zhou.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or discussion of specific risks and contingencies. The performance stock units granted to the new CFO are tied to revenue performance targets ending December 31, 2027, but specific target values are not disclosed in this text.
Key Facts for Investor Verification
- Deborah Andrews has been appointed permanent CFO after serving as Interim CFO since March 2025.
- The new CFO's compensation package includes a $1.4 million equity award with vesting conditions tied to revenue performance through 2027.
- A new Capital Stewardship Committee has been formed to oversee capital allocation strategies.
- No financial results or operational metrics are included in this specific filing.